SCHEMBL2839289

SCHEMBL2839289

COc1ccc(C=CC(=O)Nc2cc(OC)c(OC)cc2C(=O)O)cc1OC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.79
MEN1 O00255 7/20 0.78
KMT2A Q03164 7/20 0.78
HPGD P15428 6/20 0.78
ALDH1A1 P00352 5/20 0.78
KDM4E B2RXH2 5/20 0.78
SMN1; SMN2 Q16637 4/20 0.78
TP53 P04637 3/20 0.78
RAB9A P51151 3/20 0.78
CYP3A4 P08684 2/20 0.78
HIF1A Q16665 2/20 0.78
NPSR1 Q6W5P4 2/20 0.78
NPC1 O15118 2/20 0.78
PKM P14618 2/20 0.78
HSD17B10 Q99714 2/20 0.78
MAPK1 P28482 2/20 0.78
CYP1A2 P05177 2/20 0.78
CYP2C9 P11712 1/20 0.78
CYP2C19 P33261 1/20 0.78
ABCC4 O15439 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2839285 1.00 MAPT (0.79) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL21024672 0.91 MAPT (0.74) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL8638748 0.90 ALDH1A1 (0.67) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL8638736 0.90 ALDH1A1 (0.67) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL2844767 0.89 MEN1 (0.77) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL2844771 0.89 MEN1 (0.77) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL15396445 0.89 MAPT (0.74) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL4669878 0.89 MEN1 (0.77) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL8640599 0.89 MEN1 (0.77) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL13712369 0.88 MEN1 (0.79) MAPTMEN1KMT2AHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2799427-B1 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2018-07-04 EP disclosed
US-9561201-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2017-02-07 US disclosed
US-20140357628-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-12-04 US disclosed
EP-2799427-A1 Therapeutic compounds Fibrotech Therapeutics PTY LTD (AU) 2014-11-05 EP disclosed
US-8765812-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-07-01 US disclosed
EP-2035369-B1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-06-25 EP disclosed
CN-101600683-B Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD AU 2013-06-12 CN disclosed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed
EP-2035369-A1 THERAPEUTIC COMPOUNDS Fibrotech Therapeutics PTY LTD (AU) 2009-03-18 EP disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357628-A1 THERAPEUTIC COMPOUNDS NFATC1, AADAC, NAT1 MAPT 2890/4885MEN1 2604/4885KMT2A 1715/4885
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC MAPT 3019/4885MEN1 2640/4885KMT2A 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.